Saliva microRNA Profile in Children with and without Severe SARS-CoV-2 Infection

Steven D. Hicks, Dongxiao Zhu, Rhea Sullivan, Nirupama Kannikeswaran, Kathleen L. Meert, Wei Chen, Srinivasan Suresh, Usha SethuramanInternational Journal of Molecular Sciences 2023 · DOI

TL;DR

This study investigates salivary microRNA (miRNA) profiles in children infected with SARS-CoV-2 to identify potential biomarkers for severe disease. They found that specific miRNAs are significantly downregulated in children with severe COVID-19, suggesting a link between these molecules and disease severity.

What Problem Does This Paper Address?

The COVID-19 pandemic has highlighted the challenge of predicting disease severity, especially in children, where symptoms can be subtle and mimic other common infections. Early identification of children at risk for severe outcomes (like respiratory failure or shock) is crucial for timely intervention and improved patient care. While biomarkers exist for adults, there's a lack of understanding regarding such markers in pediatric COVID-19. This paper addresses this gap by exploring salivary miRNAs as a non-invasive and potentially informative biomarker for predicting severe COVID-19 in children.

Methods

The researchers employed a prospective, observational study design, collecting saliva samples from children diagnosed with SARS-CoV-2 infection at two children's hospitals. Saliva samples were processed using a standard RNA extraction protocol, and miRNA profiles were quantified using RNA sequencing. The core analytical approach involved comparing the expression levels of known human miRNAs between children with severe outcomes and those with non-severe outcomes. Statistical analysis included Wilcoxon rank sum testing to identify differentially expressed miRNAs (with a fold change of ≥2 and adjusted p-value < 0.05) and two-dimensional partial least squares discriminant analysis (PLSDA) to visualize overall miRNA profile differences. Gene ontology pathway enrichment analysis was performed to understand the biological relevance of the identified miRNAs.

Datasets

The study utilized data from 197 children infected with SARS-CoV-2, categorized into severe (n=45) and non-severe (n=152) groups. The data comprised salivary miRNA profiles obtained through RNA sequencing. No new benchmark datasets were introduced; the study focused on analyzing existing miRNA data from a clinical cohort.

Key Insights and Ideas

  • Saliva as a viable biomarker source: The study reinforces the utility of saliva as a non-invasive and child-friendly medium for biomarker discovery, aligning with previous research in other pediatric conditions.
  • miRNA downregulation in severe COVID-19: A key finding is the consistent downregulation of a majority of differentially expressed miRNAs in children with severe COVID-19, supporting the "sponge hypothesis" where viruses might manipulate host miRNAs.
  • Specific miRNAs linked to severity: The identification of specific miRNAs (miR-4495, miR-296-5p, miR-548ao-3p, and miR-1273c) with the largest between-group differences is significant, pointing towards their potential as direct indicators of disease severity.
  • Biological pathways implicated: The enrichment analysis revealing pathways like viral processing, TGF-beta signaling, and Fc-gamma receptor signaling suggests that these miRNAs play roles in critical host responses to SARS-CoV-2 infection.

Key Results

  • Out of 2652 known human miRNAs, 1606 (60%) were measured in the saliva samples.
  • A total of 43 miRNAs showed a ≥2-fold difference in expression between severe and non-severe cases, with an adjusted p-value < 0.05.
  • The majority of these differentially expressed miRNAs (31 out of 43, or 72%) were downregulated in severe cases.
  • The most significant differences were observed for miR-4495, miR-296-5p, miR-548ao-3p, and miR-1273c.
  • These four miRNAs were enriched for 32 gene ontology pathways, including viral processing, transforming growth factor beta signaling, and Fc-gamma receptor signaling.

Limitations and Future Work

The authors acknowledge several limitations:

  • Generalizability: The study was conducted at two large academic children's hospitals, which may limit the generalizability of findings to outpatient settings with milder disease prevalence.
  • Convenience Sampling: The use of convenience sampling might have influenced the results.
  • Lack of Uninfected Controls: The study did not include children without SARS-CoV-2 infection as controls, focusing solely on comparing disease severity within infected individuals.
  • Variant Impact: The study was conducted during the predominance of Delta and Omicron variants, and it remains unclear if these miRNA perturbations will persist with future variants.
  • Timing of Sample Collection: Saliva samples were collected at the time of clinical presentation (median 3 days post-symptom onset). While no correlation was found with days since onset, the utility of measurements outside this window is unknown.
  • Potential for Relapse: A small portion of children classified as non-severe might have experienced a relapse of severe symptoms later.
  • Validation: The findings were preliminary RNA sequencing results and require validation through quantitative real-time polymerase chain reactions in an external cohort.

Future work should focus on validating these findings in larger, diverse cohorts, investigating longitudinal miRNA changes to track disease trajectory and recovery, and exploring the precise mechanisms by which these miRNAs influence COVID-19 severity. The ultimate goal is to determine the utility of salivary miRNAs as reliable biomarkers for predicting severe COVID-19 in children.

Summary updated

Abstract

Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) may impair immune modulating host microRNAs, causing severe disease. Our objectives were to determine the salivary miRNA profile in children with SARS-CoV-2 infection at presentation and compare the expression in those with and without severe outcomes. Children <18 years with SARS-CoV-2 infection evaluated at two hospitals between March 2021 and February 2022 were prospectively enrolled. Severe outcomes included respiratory failure, shock or death. Saliva microRNAs were quantified with RNA sequencing. Data on 197 infected children (severe = 45) were analyzed. Of the known human miRNAs, 1606 (60%) were measured and compared across saliva samples. There were 43 miRNAs with ≥2-fold difference between severe and non-severe cases (adjusted <i>p</i>-value < 0.05). The majority (31/43) were downregulated in severe cases. The largest between-group differences involved miR-4495, miR-296-5p, miR-548ao-3p and miR-1273c. These microRNAs displayed enrichment for 32 gene ontology pathways including viral processing and transforming growth factor beta and Fc-gamma receptor signaling. In conclusion, salivary miRNA levels are perturbed in children with severe COVID-19, with the majority of miRNAs being down regulated. Further studies are required to validate and determine the utility of salivary miRNAs as biomarkers of severe COVID-19.
BibTeX
@article{hicks2023saliva,
  author = {Steven D. Hicks and Dongxiao Zhu and Rhea Sullivan and Nirupama Kannikeswaran and Kathleen L. Meert and Wei Chen and Srinivasan Suresh and Usha Sethuraman},
  title = {{Saliva microRNA Profile in Children with and without Severe SARS-CoV-2 Infection}},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24098175},
}
Figure